CHE trades 11.2% below Wall Street's consensus target of $554.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CHE achieves its forward estimates and maintains a stable P/E multiple of 19.6x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Chemed Corporation (CHE) has a Wall Street consensus price target of $554.00, based on estimates from 9 covering analysts. With the stock currently trading at $498.09, this represents a potential upside of +11.2%. The company has a market capitalization of $6.61B.
Analyst price targets range from a low of $475.00 to a high of $633.00, representing a 29% spread in expectations. The median target of $554.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CHE trades at a trailing P/E of 27.0x and forward P/E of 19.6x. Analysts expect EPS to grow +24.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $572.19, with bear and bull scenarios of $360.48 and $753.92 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ADUSAddus HomeCare Corporation | $2.1B | $114.93 | $118.33 | +3.0% | Buy | 16.3x | 16 |
 ENSGThe Ensign Group, Inc. | $10.2B | $175.46 | $215.00 | +22.5% | Buy | 22.5x | 13 |
 SCIService Corporation International | $10.8B | $77.85 | $105.00 | +34.9% | Buy | 18.6x | 10 |
 CSVCarriage Services, Inc. | $503M | $31.72 | $48.00 | +51.3% | Buy | 9.4x | 7 |
 HCSGHealthcare Services Group, Inc. | $1.5B | $21.25 | $26.50 | +24.7% | Hold | 17.7x | 15 |
 OPCHOption Care Health, Inc. | $3.7B | $23.34 | $28.43 | +21.8% | Buy | 12.4x | 15 |
 UNHUnitedHealth Group Incorporated | $337.2B | $371.29 | $473.89 | +27.6% | Buy | 18.7x | 52 |
 HUMHumana Inc. | $45.0B | $374.80 | $418.53 | +11.7% | Hold | 40.9x | 44 |
 CVSCVS Health Corp. | $109.6B | $85.86 | $111.20 | +29.5% | Buy | 10.7x | 41 |
 MCKMcKesson Corporation | $105.0B | $880.50 | $953.00 | +8.2% | Buy | 19.7x | 31 |
Quick answers to the most common questions about buying CHE stock.
Chemed Corporation (CHE) has a consensus 12-month price target of $554, implying 11.2% upside from $498.09. The 9 analysts covering CHE see moderate appreciation potential.
CHE has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $554 implies 11.2% upside from current levels.
With a forward P/E of 19.5752x, CHE trades at a relatively low valuation. The consensus target of $554 implies 11.2% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $633 for CHE, while the most conservative target is $475. The consensus of $554 represents the median expectation. Our quantitative valuation model projects a bull case target of $754 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CHE is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHE stock forecast based on 9 Wall Street analysts shows a consensus price target of $554, with estimates ranging from $475 (bear case) to $633 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $572, with bear/bull scenarios of $360/$754.
Our quantitative valuation model calculates CHE's fair value at $572 (base case), with a bear case of $360 and bull case of $754. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
CHE trades at a forward P/E ratio of 19.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 27.0x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CHE, with a "Hold" consensus rating and $554 price target (11.2% upside). 3 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHE analyst price targets range from $475 to $633, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $554 consensus represents the middle ground. Our model's $360-$754 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.